Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
← catalyst calendarNCT05245500 · readout in 478 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
336estimated
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-06-09 | actual | When the study began enrolling |
| Primary completion | 2027-12-10 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-10 | estimated | The whole study's end, after follow-up |
| First posted | 2022-02-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Mesothelioma
- Non Small Cell Lung Cancer
- Malignant Peripheral Nerve Sheath Tumors
- Solid Tumor
- Pancreatic Adenocarcinoma
- Advanced Solid Tumor
Intervention
- Drug: MRTX1719
Primary outcomes
what the primary-completion date above is the date OFNumber of Patients who Experience Dose-Limiting Toxicity
measured 21 days
Number of patients who experience a treatment-related adverse event
measured Up to 2 years
Objective response rate (ORR)
measured 2 years
Duration of response (DOR)
measured 2 years
Progression free survival (PFS)
measured 2 years
Overall survival (OS)
measured 2 years
Number of Patients With Clinically Significant Laboratory Assessments
measured Up to 4 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed